Trial ID or NCT#

NCT01632527

Status

NOT RECRUITING

Purpose

The purpose of this Phase I/II study is to investigate the safety and preliminary efficacy of unilateral subretinal transplantation of HuCNS-SC cells in subjects with geographic atrophy secondary to age-related macular degeneration.

Official Title

Phase I/II Study of the Safety and Preliminary Efficacy of Human Central Nervous System Stem Cells (HuCNS-SC) Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration

Eligibility Criteria

Ages Eligible for Study: Older than 50 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Theodore Leng, MD, FACS
Retina specialist, Ophthalmologic surgeon, Cataract specialist, Ophthalmologist
Assistant Professor of Ophthalmology and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Lorella Cabael
(650) 498-4486